RedHill Biopharma Completes Enrollment for COVID-19 U.S. Phase 2 Study with Opaganib
RedHill Biopharma Ltd (Nasdaq: RDHL), a specialty biopharmaceutical company, today announced that the U.S. Phase 2 study with opaganib (Yeliva®, ABC294640) in patients hospitalized with severe COVID-19 pneumonia has completed…